EP PerMed is European Partnership dedicated to Personalised Medicine (PM). It supports PM-related R&I, but also facilitates and accelerates all steps so that PM achievements successfully pass through the full value continuum to be implemented in sustainable health systems for the benefit of people and societies.
This call aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity. EP PerMed will fund innovation projects in human health that focus on multimodal data usage for PM approaches aiming to provide more efficient and personalised management of patients with multimorbidity, having at least two chronic diseases that require management.
Each consortium must include at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the EP PerMed RITC2026 call. Each partner will be supported by the funding agency of their respective country.
International Applications are made through EP PerMed Submission Platform
National Applications are made through TÜBİTAK Online Application system
Call Timeline:
Deadline for the first stage of international proposal submission (pre-proposal): 12 January 2026 (14:00, CET)
Deadline for the first stage of national applications: 16 January 2026 (23:59 UTC+3)
Deadline for the-signature (pre-proposal): 21 January 2026 (23:59 UTC+3)
Deadline for the second stage of international proposal submission*: 27 April 2026 (14:00, CEST)
*The deadline for the second stage national application, to be carried out through TÜBİTAK PBS for projects with positive results in the international evaluation of the second stage, will be announced by TÜBİTAK to the relevant parties.
